Cytokine-mobilized peripheral blood CD34+Thy-1+Lin- human hematopoietic stem cells as target cells for transplantation-based gene therapy.
Gene-therapy of blood-borne disorders may be best achieved using hematopoietic stem cells (HSC) which have extensive self renewal potential as well as multilineage repopulating potential as a cellular target. The human HSC, which is CD34+Thy-1+Lin- has been isolated from fetal, adult bone marrow and cytokine-mobilized peripheral blood (MPB) (1-3). Results presented in this study show that the degree of mobilization of HSC into peripheral blood of cancer patients is highly variable and that the combined use of high dose chemotherapy and GM-CSF as a mobilization strategy is superior to the use of G-CSF with regard to the mobilization of true HSC. A multistep cell isolation procedure has been developed which utilizes high speed flow-cytometric cell sorting and allows the isolation of sufficient numbers of HSC from MPB to permit their use as an hematopoietic graft for clinical transplantation. Hematopoietic stem cells isolated from MPB are capable of self-renewal and differentiation into multiple hematopoietic lineages as shown by their behavior in both in vitro and in vivo assays. Mobilized PB mononuclear cells isolated from cancer patients are frequently contaminated with tumor cells. Using this cell isolation procedure, HSC preparations from patients with multiple myeloma have been created with greatly reduced tumor cell burdens. These CD34+Thy-1+Lin- cells are capable of being stably transduced at high efficiency (32-75%) by co-culture on a cell line producing recombinant retroviruses containing the neomycin-resistant gene. These HSC cell populations are likely ideal targets for hematopoietic cell-based gene therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34 / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D001853:Bone Marrow / Q000196:embryology; D001854:Bone Marrow Cells; D003114:Colony-Forming Units Assay; D016207:Cytokines / Q000494:pharmacology*; D005333:Fetus; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods; D015791:HLA-A3 Antigen / Q000032:analysis; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000276:immunology; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D009369:Neoplasms / Q000628:therapy; D016133:Polymerase Chain Reaction; D018800:Thy-1 Antigens / Q000032:analysis; D013950:Thymus Gland / Q000166:cytology / Q000276:immunology; D014182:Transplantation, Autologous; D014183:Transplantation, Heterologous
D015703:Antigens, CD; D018952:Antigens, CD34; D015415:Biomarkers; D016207:Cytokines; D015791:HLA-A3 Antigen; D018800:Thy-1 Antigens